Form 4: Avalo Therapeutics Director Samantha Truex Granted Stock Options

Avalo Therapeutics, Inc. Director Samantha Truex was granted 20,100 stock options with an exercise price of $4.47, which will vest fully on the first anniversary of the grant date.

Summary

• Samantha Truex, a Director at Avalo Therapeutics, Inc. (AVTX), was granted 20,100 stock options.
• The stock options have an exercise price of $4.47 per share.
• The grant date for these options is June 17, 2025.
• The options will vest 100% on the first anniversary of the grant date, subject to Ms. Truex's continued service.
• The expiration date for these stock options is June 17, 2035.
• Following this transaction, Ms. Truex beneficially owns 20,100 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The document reports a routine compensation event (stock option grant) for a director, which is generally viewed as a neutral to slightly positive development as it aligns management/director interests with shareholders. There are no negative surprises or significant new risks disclosed.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, as the options gain value only if the company's stock price increases above the exercise price.
• This is a standard form of compensation for directors, indicating ongoing commitment and incentivizing long-term performance.

Risks

• The value of the stock options is contingent on the future market price of Avalo Therapeutics' common stock exceeding the exercise price of $4.47; if the stock price remains below this level, the options may expire worthless.
• The options are subject to forfeiture if the director's service to the company ceases before the vesting date of June 17, 2026.

Future Outlook

The grant of stock options provides a future incentive for the director, aligning their financial interests with the long-term growth and stock performance of Avalo Therapeutics, as the options will only yield value if the company's stock price appreciates above the exercise price by the expiration date.

Industry Context

The granting of stock options to directors is a common and widely accepted practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies. It serves as a key component of executive and director compensation packages, designed to attract and retain talent while incentivizing performance tied to shareholder value creation.

Comparison to Industry Standards

• The practice of granting stock options to directors is standard across the industry, including companies like Pfizer, Johnson & Johnson, and smaller biotech firms, as a means of non-cash compensation.
• The vesting schedule (100% on first anniversary) is a common structure for director equity grants, aiming to ensure continued service and long-term commitment.
• Without specific data on average director option grants for companies of similar market capitalization and stage of development as Avalo Therapeutics, a direct quantitative comparison of the grant size (20,100 options) is not feasible from this document alone. However, it appears to be a routine grant.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options aligns the director's financial incentives with the company's stock performance, potentially leading to decisions that enhance shareholder value.
• Employees: While not directly impacting employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The stock options will vest on June 17, 2026, provided Samantha Truex continues her service as a director.
• Upon vesting, Ms. Truex will have the right to exercise the options and purchase common stock at the exercise price of $4.47 per share until the expiration date of June 17, 2035.

Key Dates

Recommendation

Keywords

Avalo Therapeutics, AVTX, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Derivative Securities